China Out-Licensing Report 2026

The Headline Numbers

If a single chart captured the last three years of global pharma business development, it would be the vertical climb in China out-licensing. The numbers are no longer a niche story for Asia-watchers — they are reshaping where the industry sources its pipeline.

By industry deal-tracker counts, Chinese drugmakers signed roughly 157 out-licensing deals worth about $136 billion in 2025 — a near-tenfold leap in disclosed value from the ~$51.9 billion across 94 deals in 2024 (itself up about 26% on 2023). And the curve has not flattened: cross-border out-licensing by Chinese biotechs reportedly reached about $60 billion in the first quarter of 2026 alone, up roughly 73% year over year — compressing nearly half of 2025’s entire annual total into three months.

The share statistic is the one to circle. China now accounts for roughly a third of global out-licensing deal value, up from roughly a fifth in 2023-2024, and is the origin of a fast- rising share of all newly licensed assets — by deal count, some Q1 2026 reads put China-origin transactions at close to half of global pharma BD activity. A decade ago, China was where Western pharma sold finished drugs. Today it is increasingly where Western pharma buys its next ones.

Why the Surge, and Why Now

The boom is not a fluke of one or two megadeals; it is the maturation of a decade of Chinese R&D investment colliding with a Western industry under acute pipeline pressure. Three forces converged:

• A patent cliff on the buy side. Big Pharma faces a wave of expiries on blockbuster franchises and needs to refill pipelines quickly. China offers clinical-stage, de-risked assets at a fraction of the cost of a Western bolt-on acquisition — we cover the buyer math in our guide to in-licensing China biotech assets.
• A supply boom on the sell side. Chinese biotechs now generate genuinely competitive, sometimes best-in-class molecules — particularly in ADCs and bispecifics — and a tougher domestic funding market pushes them to monetize ex-China rights early rather than build global commercial operations alone.
• Speed and cost of clinical execution. Faster, lower-cost trials get a Chinese asset to human proof-of-concept sooner, turning an early molecule into a licensable, partially de-risked product years ahead of a Western equivalent — a dynamic amplified by AI-native discovery, as covered in our Chinese AI drug discovery guide.

The result is a textbook seller’s market for the best assets and a buyer’s market for everything else — which is precisely why disciplined sourcing and diligence separate the deals that create value from the ones that destroy it.

The Biggest Deals of 2025-2026

The table below collects the most notable China→West out-licensing transactions of the period. Every figure is drawn from company announcements and major industry deal trackers; biobucks figures represent total potential value including contingent milestones, not cash paid. This is the analytical companion to our live China outbound licensing tracker, which maintains the running list as new deals land.

*BMS upfront plus ~$2B in non-contingent anniversary payments through 2028. **Pfizer upfront plus a ~$100M equity investment and up to ~$4.8B in milestones. Figures rounded; biobucks are potential, not guaranteed.

Two patterns leap out. First, the PD-1/PD-L1×VEGF bispecific class alone accounts for several of the largest deals — Summit –Akeso, BMS–BioNTech, and Pfizer–3SBio — making it the single hottest competitive battleground in immuno-oncology, and one almost entirely sourced from China. Second, the obesity/cardiometabolic entry (AstraZeneca–CSPC) signals that the deal wave has broken out of oncology into the most commercially valuable therapeutic category of the decade.

The Modality & Therapeutic Breakdown

Where is the money concentrated? Oncology remains the overwhelming center of gravity. By some estimates, cancer assets represented roughly two-thirds to 70% of disclosed China out-licensing value in 2025. Within oncology, two modalities dominate the premium tier:

• Antibody-drug conjugates (ADCs). China has become the world’s ADC workshop — by some trackers Chinese originators now drive the large majority of global ADC licensing activity. The Merck–Kelun franchise (built around the TROP2 ADC sac-TMT and a seven-asset platform deal) is the archetype.
• PD-1/PD-L1×VEGF bispecifics. The class that began with Akeso’s ivonescimab and now spans Summit, BMS, and Pfizer deals. The thesis — combining checkpoint blockade with anti-angiogenesis in one molecule — has made these among the most contested assets in the industry.

The most important new vector is cardiometabolic and obesity. The AstraZeneca–CSPC peptide alliance — up to ~$18.5 billion for ex-China rights to as many as eight long-acting GLP-1/GIP-class assets — drags the GLP-1 gold rush into China sourcing. Expect this category to be the fastest-growing share of out-licensing value through 2026, as Western players who missed the first GLP-1 wave look to China for next-generation and differentiated peptides. Autoimmune, respiratory (the GSK–Hengrui COPD asset), and CNS programs round out a broadening base.

Deal Structure: Small Upfronts, Big Biobucks

The defining structural feature of China out-licensing is the gap between the cash that changes hands today and the headline number in the press release. Across the marquee 2025 deals, upfronts typically ran from the low hundreds of millions to ~$1.5 billion, against total potential values of $5-18.5 billion. The GSK–Hengrui deal is the clearest illustration: ~$500 million upfront against up to ~$12.5 billion in potential value — barely 4% paid at signing.

For anyone underwriting these transactions, two disciplines follow directly:

• Discount the biobucks hard. The probability-weighted value of a development, regulatory, and sales milestone stack is a fraction of the headline. The honest number is upfront plus a heavily risk-adjusted milestone expectation — not the figure in the announcement.
• Read the territory split. Most of these are ex-China (or ex-Greater China) licenses: the originator keeps the home market and monetizes the rest of the world. That structure is what makes the deals politically and commercially workable, and it is a feature, not a limitation.

Increasingly, the savviest structures also lean on option-to-license mechanics — a smaller payment for the right to take full rights after a defined data readout — which lets buyers stage capital against de-risking. We help structure exactly these terms in our out-licensing advisory.

Buyers and Originators: A League Table

Step back from individual deals and a clear set of repeat players emerges on both sides of the table.

On the buyer side, the most active acquirers of Chinese assets in 2025-2026 have been the large-cap Western players with the deepest pipeline gaps: AstraZeneca (the standout, with two CSPC deals and a long China footprint), GSK, Merck, Pfizer, and BMS. Their common thread is a near-term patent cliff and a strategic decision to treat China as a primary, not opportunistic, sourcing channel — context we develop in our Top Chinese Biotech Companies guide.

On the originator side, a handful of Chinese houses have become serial out-licensers: Jiangsu Hengrui (whose GSK pact was among the largest of the year and which has done a string of prior licensing deals), CSPC, Akeso, Kelun-Biotech, and 3SBio. These are no longer one-asset stories; they are platforms that have learned to package, de-risk, and out-license repeatedly — a maturity that itself signals the sector’s durability.

The pattern to watch: as the league of credible originators deepens, the negotiating leverage on the best assets is shifting toward the Chinese side. Buyers who built relationships early — and who can move fast on diligence — are capturing assets before they reach a competitive auction.

The BIOSECURE & Geopolitics Context

No China out-licensing report is complete without the policy overlay. The headline event of the period was the BIOSECURE Act becoming law in December 2025, enacted as part of the FY2026 National Defense Authorization Act. The Act restricts US federal procurement and grants involving designated “biotechnology companies of concern,” tying the definition to the Department of Defense’s 1260H list and creating a process to designate more entities over a multi-year phase-in.

Crucially for dealmakers, what the law targets and what it leaves alone are very different. As enacted, it focuses on named service, genomics, and manufacturing providers used by federally funded entities — not on out-licensing rights to a molecule. In-licensing a Chinese-originated asset is legally distinct from outsourcing sensitive data or manufacturing to a restricted vendor. The clearest proof is in the data itself: the deal wave hit record highs through the entire BIOSECURE debate and its enactment. The market has read the law as a friction to structure around, not a wall.

That said, the direction of travel matters. Policy can tighten, additional companies can be added to the relevant lists, and buyers must build deals that survive a harder line — clean ex-China territory splits, data and supply arrangements that avoid restricted vendors, and terms that anticipate further designations. We unpack the specifics in our BIOSECURE Act analysis.

The 2026 Outlook

Where does this go from here? On current trajectory, 2026 is on pace to match or exceed 2025’s record. The ~$60 billion struck in the first quarter alone — if even loosely sustained — points to another year above the $100 billion mark, and quite possibly a new high. The drivers behind the surge (Western patent cliffs, a deep Chinese supply of clinical-stage assets, and the speed-and-cost advantage of Chinese development) are structural, not cyclical.

Three shifts to watch through the rest of the year:

• Obesity goes mainstream as a China-sourcing category. The AstraZeneca–CSPC deal will not be the last. Expect more Western players to source next-generation metabolic peptides from China.
• Upfronts creep higher for the best assets. As competition for premium ADCs and bispecifics intensifies, originators will extract larger cash components — narrowing, slightly, the characteristic upfront-to-total gap on top-tier deals.
• Acquisitions, not just licenses. A handful of buyers are beginning to consider outright acquisition of Chinese-rooted assets and platforms — a more complex path, but one that removes the originator from the cap table entirely.

The base case is continuity and growth. The risk case is a sharp geopolitical escalation that forces a structural rethink — which is exactly why deal terms should be built to absorb it.

What It Means for Dealmakers

For a Western buyer, the strategic conclusion is unambiguous: China is now a primary sourcing channel for clinical-stage innovation, and treating it as optional means ceding the best assets to faster, better- networked competitors. The execution, however, is where deals are won or lost. Four disciplines define the work:

• Source before the auction. The best assets are frequently spoken for before they appear in Western deal channels. Proximity and relationships in Greater China are decisive — and the reason a competitive auction is usually a sign you are already late.
• Diligence data and IP rigorously. Scrutinize data provenance, IP ownership and inventorship, and whether the clinical package will translate to FDA/EMA standards. The same rigor as any deal, with added attention to cross-border data and quality.
• Structure for contingency. Design milestone and royalty schedules, territory splits, and option mechanics that reflect cross-border tax, regulatory, and political realities.
• Navigate the policy overlay. Build deals that remain robust if BIOSECURE-era restrictions tighten or additional designations land.

For a Chinese originator, the mirror logic applies: the firms that capture the most value are those that package and de-risk assets to Western diligence standards before going to market, and that run a competitive, well-advised process rather than accepting the first term sheet. This is the core of what we do — see our out-licensing service and our broader in-licensing playbook.

The Bottom Line

China out-licensing has crossed from emerging trend to structural reality. A record ~$136 billion in 2025, a blistering ~$60 billion start to 2026, and roughly a third of all global out-licensing value now originating in China — these are not statistics a serious BD organization can treat as someone else’s market. The combination of Western pipeline pressure and a deep, fast, increasingly sophisticated Chinese supply of assets is durable, and the geopolitical friction widens rather than closes the opening for those who can operate credibly across the border.

The dealmakers who win the next phase will be those who source the best Chinese assets early, diligence them without compromise, and structure transactions that hold up under political pressure. We maintain the live deal list in our outbound licensing tracker and publish this report annually as the citable benchmark for the market. If you are evaluating a China-sourced asset or running an out-licensing process, talk to our team.